LdtMav2, a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems

Rohini Mattoo, Evan P. Lloyd, Amit Kaushik, Pankaj Kumar, Julie L. Brunelle, Craig A. Townsend, Gyanu Lamichhane

Research output: Contribution to journalArticle

Abstract

Aim: Mycobacterium avium infections, especially in immune-compromised individuals, present a significant challenge as therapeutic options are limited. In this study, we investigated if M. avium genome encodes nonclassical transpeptidases and if newer carbapenems are effective against this mycobacteria. Materials & methods: Biochemical and microbiological approaches were used to identify and characterize a nonclassical transpeptidase, namely L,D-transpeptidase, in M. avium. Results & conclusion: We describe the biochemical and physiological attributes of a L,D-transpeptidase in M. avium, LdtMav2. Suggestive of a constitutive requirement, levels of LdtMav2, a L,D-transpeptidase in M. avium, remain constant during exponential and stationary phases of growth. Among β-lactam antibacterials, only a subset of carbapenems inhibit LdtMav2 and tebipenem, a new oral carbapenem, inhibits growth of M. avium.

Original languageEnglish (US)
Pages (from-to)595-607
Number of pages13
JournalFuture Microbiology
Volume12
Issue number7
DOIs
StatePublished - Jun 1 2017

Keywords

  • carbapenem
  • L,D-transpeptidase
  • mycobacteria
  • Mycobacterium avium
  • peptidoglycan
  • tebipenem

ASJC Scopus subject areas

  • Microbiology
  • Microbiology (medical)

Fingerprint Dive into the research topics of 'Ldt<sub>Mav2</sub>, a nonclassical transpeptidase and susceptibility of Mycobacterium avium to carbapenems'. Together they form a unique fingerprint.

  • Cite this